1.0The Medical Xchangehttps://themedicalxchange.com/en/New Data from IMAgINE 1 Trial Provide Insights on Biologic Use in Pediatric Crohn’s Disease - The Medical Xchangerich600338<blockquote class="wp-embedded-content" data-secret="cSPVY8J5Ac"><a href="https://themedicalxchange.com/en/2014/05/23/digestive-disease-week-ddw-2014-3/">New Data from IMAgINE 1 Trial Provide Insights on Biologic Use in Pediatric Crohn’s Disease</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://themedicalxchange.com/en/2014/05/23/digestive-disease-week-ddw-2014-3/embed/#?secret=cSPVY8J5Ac" width="600" height="338" title="“New Data from IMAgINE 1 Trial Provide Insights on Biologic Use in Pediatric Crohn’s Disease” — The Medical Xchange" data-secret="cSPVY8J5Ac" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript">
/* <![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
//# sourceURL=https://themedicalxchange.com/wp-includes/js/wp-embed.min.js
/* ]]> */
</script>
https://themedicalxchange.com/wp-content/uploads/2014/05/EX_7008_DDW_Crohns_Fig_1.PNG960720Chicago – A series of new analyses drawn from the IMAgINE 1 trial have generated insight on how best to employ biologic therapy in children with Crohn’s disease. In new data presented at the 2014 DDW on IMAgINE 1, which randomized 192 children from age 6 to 17 years to a standard or low-dose regimen of adalimumab, concomitant immunologic modulators were not found to improve clinical remission rates, once-weekly dosing was often effective when every-other-week dosing was not, and higher doses of adalimumab led to higher rates of corticosteroid-free remission.